Teriparatide injection - Asahi Kasei Pharma
Alternative Names: hPTH - Asahi Kasei Pharma; MN-10-T; PTH injection - Asahi Kasei Pharma; TeriboneLatest Information Update: 02 Oct 2021
At a glance
- Originator Asahi Kasei Pharma Corp
- Developer Asahi Kasei Pharma Corp; Dong-A ST
- Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
- Mechanism of Action Parathyroid hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Osteoporosis
Most Recent Events
- 31 Mar 2020 Nagasaki University Hospital completes a clinical trial for Osteoporosis (In the elderly) in Japan (UMIN000020584)
- 27 Nov 2019 Asahi Kasei Pharma announces intention to launch teriparatide 28.2µg subcutaneous autoinjector in Japan in December 2019
- 23 Sep 2019 Registered for Osteoporosis (In adults) in Japan (SC)